Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
暂无分享,去创建一个
R. Greil | H. Einsele | A. Hinke | S. Nolte | D. Niederwieser | R. Hájek | T. Jelínek | H. Ludwig | T. Melchardt | S. Knop | E. Gunsilius | W. Willenbacher | H. Rumpold | A. Egle | K. Weisel | W. Pönisch | M. Schreder | A. Petzer | N. Zojer | L. Pour | D. Lechner | A. Meckl | K. J. Krenosz | Sandra Nolte
[1] R. Greil,et al. Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma , 2019, British Journal of Cancer.
[2] M. Dimopoulos,et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma , 2019, Blood Cancer Journal.
[3] A. Gnanasakthy,et al. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016). , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[4] M. Dimopoulos,et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.
[5] P. Fayers,et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. , 2019, European journal of cancer.
[6] G. Morgan,et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study , 2018, British Journal of Haematology.
[7] C. Cleeland,et al. Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma , 2018, American journal of hematology.
[8] K. Noonan,et al. Understanding and treating concerns and symptoms in patients with multiple myeloma , 2017 .
[9] Paul McCrone,et al. The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer , 2017, BMJ Open.
[10] O. Landgren,et al. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes , 2017, Journal of internal medicine.
[11] M. Dimopoulos,et al. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Palumbo,et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[13] S. Leyvraz,et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide , 2015, Haematologica.
[14] A. Gnanasakthy,et al. Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient. , 2015, JAMA oncology.
[15] Michael L. Wang,et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.
[16] T. R. Osborne,et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life , 2014, BMC Cancer.
[17] P. Sonneveld,et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents , 2013, Leukemia.
[18] D. Esseltine,et al. Health‐related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial , 2012, European journal of haematology.
[19] P. Fayers,et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2012, European journal of cancer.
[20] R. Fonseca,et al. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. , 2012, Journal of pain and symptom management.
[21] H. Goldschmidt,et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Strasser-Weippl,et al. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma , 2008, European journal of haematology.
[23] C. Gotay,et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Hájek,et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. , 2007, European journal of cancer.
[25] D. Esseltine,et al. Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. , 2007, Journal of clinical epidemiology.
[26] A. Protopopov,et al. The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.
[27] M. Mori,et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Douglas G Altman,et al. The logrank test , 2004, BMJ : British Medical Journal.
[29] D. Machin,et al. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? , 1997, Quality of Life Research.
[30] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[31] M. Lawton,et al. Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.
[32] S. Katz,et al. STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.
[33] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[34] L. Schwartz,et al. Recommendations for the assessment of progression in randomised cancer treatment trials. , 2009, European journal of cancer.
[35] D. Osoba,et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. , 2005, European journal of cancer.
[36] P. Viens,et al. Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. , 1997, British Journal of Cancer.
[37] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.